 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 1827 | 回復(fù): 14 | |||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | |||
zlwcw木蟲 (著名寫手)
|
[交流]
【轉(zhuǎn)帖】查爾斯河擬16億美元收購(gòu)無錫藥明康德 已有14人參與
|
||
|
查爾斯河擬16億美元收購(gòu)無錫藥明康德 2010-04-26 11:18:47 來源: 網(wǎng)易財(cái)經(jīng) 跟貼 1 條 手機(jī)看股票 網(wǎng)易財(cái)經(jīng)4月26日訊 據(jù)消息人士透露，美國(guó)查爾斯河試驗(yàn)室國(guó)際公司（Charles River Laboratories International Inc），同意以16億美元收購(gòu)無錫藥明康德新藥開發(fā)有限公司。 查爾斯河每股21.25美元的收購(gòu)價(jià)，包括11.25美元的現(xiàn)金支付和10美元的股票購(gòu)買價(jià)。據(jù)消息人士透露收購(gòu)，雙方將會(huì)在今天晚些時(shí)候正式公布交易。之前已經(jīng)有媒體報(bào)道雙方有意進(jìn)行交易，但是目前雙方的公司發(fā)言人均拒絕發(fā)布評(píng)論。 摩根大通和瑞信集團(tuán)分別擔(dān)任查爾斯河以及無錫藥明康德的顧問公司。在這宗收購(gòu)?fù)瓿芍�，無錫藥明康德將持有公司少于30%的股份。(馮易塵） Charles River Plans to Acquire WuXi AppTec April, 26, 2010 - Charles River is pleased to announce plans to acquire WuXi AppTec, creating the only global CRO to offer fully integrated drug development services from molecule creation to first-in-human testing. The combined company, which will retain the name Charles River, will offer enhanced support for your research programs through our comprehensive portfolio of early-stage drug development services and expanded global presence. WuXi AppTec is a leading drug research and development outsourcing company with significant expertise in discovery chemistry. It was established in 2000 and has steadily grown to more than 4,000 employees with operations in China and the United States. Together with Charles River, a leading global provider of both research models and associated services as well as preclinical drug development services, the combined company will have 12,000 employees, providing unparalleled support for your early-stage drug development needs. We regard this as a transformational transaction that creates value for customers by enabling you to obtain comprehensive support for your early-stage drug development needs from one company with extensive scientific expertise, depth and breadth. Further, we will be able to provide you with expanded global access to our integrated portfolio of products and services, enabling you to work within or across the locales you choose, in North America, Europe or China. This strategic combination brings together two companies with the shared mission of supporting the acceleration of your drug development efforts and a commitment to exceeding your expectations. We will continue to share additional details in the next few days on how Charles River will set a new standard in the outsourced drug development services industry. In the meantime, please view more information on www.criver.com, or contact your sales representative with any questions. We look forward to continuing to work with you and to further supporting your early-stage drug development needs. Forward-Looking Statements This document includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on current expectations and beliefs of Charles River Laboratories International, Inc. (Charles River) and WuXi PharmaTech (Cayman) Inc. (WuXi), and involve a number of risks and uncertainties that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: 1) the possibility that the companies may be unable to obtain stockholder or regulatory approvals required for the combination; 2) problems may arise in successfully integrating the businesses of the two companies; 3) the acquisition may involve unexpected costs; 4) the combined company may be unable to achieve cost synergies; 5) the businesses may suffer as a result of uncertainty surrounding the acquisition; and 6) the industry may be subject to future regulatory or legislative actions and other risks that are described in Securities and Exchange Commission (SEC) reports filed or furnished by Charles River and WuXi. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River and WuXi. Charles River and WuXi assume no obligation and expressly disclaim any duty to update information contained in this filing except as required by law. Additional Information This document may be deemed to be solicitation material in respect of the proposed combination of Charles River and WuXi. In connection with the proposed transaction, Charles River will file a preliminary proxy statement and a definitive proxy statement with the SEC. The information contained in the preliminary filing will not be complete and may be changed. Before making any voting or investment decisions, investors and security holders are urged to read the definitive proxy statement when it becomes available and any other relevant documents filed with the SEC because they will contain important information. The definitive proxy statement will be mailed to the shareholders of Charles River seeking their approval of the proposed transaction. Charles River’s shareholders will also be able to obtain a copy of the definitive proxy statement free of charge by directing a request to: Charles River Laboratories, 251 Ballardvale Street, Wilmington, MA 01887, Attention: General Counsel. In addition, the preliminary proxy statement and definitive proxy statement will be available free of charge at the SEC’s website, www.sec.gov or shareholders may access copies of the documentation filed with the SEC by Charles River on Charles River’s website at www.criver.com. Charles River and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Charles River’s directors and executive officers is available in Charles River’s proxy statement for its 2010 annual meeting of shareholders, which was filed with the SEC on March 30, 2010. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of Charles River shareholders in connection with the proposed transaction will be set forth in the preliminary proxy statement when it is filed with the SEC. This document does not constitute an offer of any securities for sale or a solicitation of an offer to buy any securities. The Charles River shares to be issued in the proposed transaction have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Charles River intends to issue such Charles River shares pursuant to the exemption from registration set forth in Section 3(a)(10) of the Securities Act. [ Last edited by zlwcw on 2010-4-26 at 21:34 ] |
回復(fù)此樓» 猜你喜歡
CSC改派-博士生交流訪學(xué)
已經(jīng)有19人回復(fù)
-
中山大學(xué)-第七醫(yī)院-招科研助理1名（基因設(shè)計(jì)和克隆、RNA合成）
已經(jīng)有0人回復(fù)
-
藥理學(xué)論文潤(rùn)色/翻譯怎么收費(fèi)?
已經(jīng)有173人回復(fù)
-
中山大學(xué)-第七醫(yī)院-招科研助理1名（基因設(shè)計(jì)和克隆、RNA合成）
已經(jīng)有1人回復(fù)
-
26考博申請(qǐng) 學(xué)or專
已經(jīng)有15人回復(fù)
-
巴黎薩克雷大學(xué)與國(guó)家留學(xué)基金委合作博士研究生項(xiàng)目-脂質(zhì)納米藥物/生物材料/多酚遞送
已經(jīng)有10人回復(fù)
-
錦州醫(yī)科大學(xué)藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有0人回復(fù)
-
錦州醫(yī)科大學(xué)藥用生物材料（專業(yè)代碼1007Z1）招收調(diào)劑考生
已經(jīng)有1人回復(fù)
-
26申博自薦
已經(jīng)有12人回復(fù)
» 本主題相關(guān)價(jià)值貼推薦，對(duì)您同樣有幫助:
- 【其他】查爾斯河與藥明康德終止16億美元并購(gòu)交易��！
已經(jīng)有6人回復(fù)
faladi
金蟲 (正式寫手)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 1324.8
- 紅花: 1
- 帖子: 441
- 在線: 77.1小時(shí)
- 蟲號(hào): 618192
- 注冊(cè): 2008-10-06
- 專業(yè): 有機(jī)合成
7樓2010-04-26 16:07:15
lou8611
至尊木蟲 (知名作家)
有機(jī)毒蟲
- 應(yīng)助: 465 (碩士)
- 金幣: 22413.3
- 紅花: 4
- 帖子: 5445
- 在線: 524.6小時(shí)
- 蟲號(hào): 92709
- 注冊(cè): 2005-09-10
- 性別: GG
- 專業(yè): 應(yīng)用有機(jī)化學(xué)
2樓2010-04-26 13:44:58
swydcgl
金蟲 (小有名氣)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 650.6
- 帖子: 278
- 在線: 25.5小時(shí)
- 蟲號(hào): 947243
- 注冊(cè): 2010-01-23
- 專業(yè): 呼吸系統(tǒng)炎癥與感染
3樓2010-04-26 13:50:23
montyjh
木蟲 (正式寫手)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 1806.5
- 散金: 100
- 紅花: 1
- 帖子: 686
- 在線: 102.8小時(shí)
- 蟲號(hào): 118828
- 注冊(cè): 2005-11-27
- 性別: GG
- 專業(yè): 有機(jī)合成
★ ★
小木蟲(金幣+0.5):給個(gè)紅包，謝謝回帖交流
kidant(金幣+1):謝謝提供信息來源 2010-04-26 16:10
小木蟲(金幣+0.5):給個(gè)紅包，謝謝回帖交流
kidant(金幣+1):謝謝提供信息來源 2010-04-26 16:10
|
http://www.criver.com/en-US/News ... ses/Pages/WuXi.aspx 確實(shí)是啊，關(guān)注 |
4樓2010-04-26 14:19:56
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 271求調(diào)劑 +4 | 生如夏花… 2026-03-22 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 085600材料與化工調(diào)劑 +9 | A-哆啦Z夢(mèng) 2026-03-23 | 15/750 |
|
|
|
[考研] 278求調(diào)劑 +4 | 我可以上岸的對(duì)?/a> 2026-03-19 | 4/200 |
|
|
|
[考研] 生物技術(shù)與工程 +3 | 1294608413 2026-03-25 | 3/150 |
|
|
|
[考研] 求調(diào)劑 一志愿 本科 北科大 化學(xué) 343 +4 | 13831862839 2026-03-24 | 5/250 |
|
|
|
[考研] 07化學(xué)280分求調(diào)劑 +7 | 722865 2026-03-23 | 7/350 |
|
|
|
[考研] 300分，材料，求調(diào)劑，英一數(shù)二 +5 | 超贊的 2026-03-24 | 5/250 |
|
|
|
[考研] 0856材料專碩353求調(diào)劑 +6 | NIFFFfff 2026-03-20 | 6/300 |
|
|
|
[考研] 300求調(diào)劑，材料科學(xué)英一數(shù)二 +5 | leaflight 2026-03-24 | 5/250 |
|
|
|
[考研] 277分求調(diào)劑，跨調(diào)材料 +3 | 考研調(diào)劑lxh 2026-03-24 | 3/150 |
|
|
|
[考研] 一志愿河北工業(yè)大學(xué)0817化工278分求調(diào)劑 +7 | jhybd 2026-03-23 | 12/600 |
|
|
|
[考研] 333求調(diào)劑 +6 | 87639 2026-03-21 | 10/500 |
|
|
|
[考研] 尋找調(diào)劑 +4 | 倔強(qiáng)芒? 2026-03-21 | 4/200 |
|
|
|
[考研] 求調(diào)劑 +3 | 13341 2026-03-20 | 3/150 |
|
|
|
[考研] 一志愿重慶大學(xué)085700資源與環(huán)境總分308求調(diào)劑 +7 | 墨墨漠 2026-03-20 | 7/350 |
|
|
|
[考研] 332求調(diào)劑 +3 | 鳳凰院丁真 2026-03-20 | 3/150 |
|
|
|
[考研] 274求調(diào)劑 +10 | S.H1 2026-03-18 | 10/500 |
|
|
|
[考研] 288求調(diào)劑 +16 | 于海海海海 2026-03-19 | 16/800 |
|
|
|
[考研] 材料學(xué)碩297已過四六級(jí)求調(diào)劑推薦 +11 | adaie 2026-03-19 | 11/550 |
|
|
|
[考研] 一志愿南理工085701環(huán)境302求調(diào)劑院校 +3 | 葵梓衛(wèi)隊(duì) 2026-03-20 | 3/150 |
|